DPP4 Inhibitors and COVID-19–Holy Grail or Another Dead End?
Alicja Krejner‐Bienias, Katarzyna Grzela, Tomasz Grzela
Abstract
A novel coronavirus disease, COVID-19, has emerged as a global public health issue. Clinical course of disease significantly correlates with the occurrence of some comorbidities, among them type 2 diabetes. According to recent structural studies the dipeptidyl peptidase 4, a key molecule in the pathophysiology of diabetes, may influence the course of COVID-19. Since DPP4 inhibitors, gliptins, are widely used in diabetes patients, the exact role of DPP4 modulation in SARS-CoV-2 infection, at least in that group, urgently needs to be clarified. In this short review, we discuss this issue with more detail.
Topics & Concepts
Dipeptidyl peptidase-4Holy GrailCoronavirus disease 2019 (COVID-19)Diabetes mellitusMedicineCoronavirusDiseaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Type 2 diabetes2019-20 coronavirus outbreakImmunologyVirologyIntensive care medicineInternal medicineInfectious disease (medical specialty)EndocrinologyOutbreakComputer scienceWorld Wide WebPeptidase Inhibition and AnalysisDiabetes Treatment and ManagementCOVID-19 Clinical Research Studies